Compare Lithium Americas Corp (LAC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 11.9× Lithium Americas Corp's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LAC | XBI | |
|---|---|---|
Market Cap | $850.38M | $10.11B |
Volume | 8,804,637 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $10.05 | $169.55 |
52-Week Low | $2.35 | $104.99 |
Typical Hold Time | 27 Days | 38 Days |
Enterprise Value | $1.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, while maintaining strong analyst support with 7 buy ratings and a $4.00 consensus price target. Recent financing activities and Thacker Pass project development provide growth catalysts amid challenging lithium market conditions.
LAC presents a high-risk opportunity with significant upside potential from its Thacker Pass project execution, though negative cash flow and lithium price volatility create near-term headwinds. The stock trades at a discount to analyst targets but requires successful project ramp-up to justify valuation.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
